A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma
10.3971/j.issn.1000-8578.2023.22.0852
- VernacularTitle:抗PD-1抗体联合治疗晚期肝细胞癌的真实世界研究
- Author:
Shishi QIAO
1
;
Tiandong KONG
;
Dan YU
;
Zhen YANG
;
Yanfeng PAN
;
Lingdi ZHAO
Author Information
1. Department of HBP, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
- Publication Type:Research Article
- Keywords:
Hepatocellular carcinoma;
Anti-PD-1 antibody;
Liver function;
Performance status;
Real world
- From:
Cancer Research on Prevention and Treatment
2023;50(3):293-297
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy, safety, and factors that might influence the efficacy of antiPD-1 antibody-based therapy in advanced hepatocellular carcinoma in the real world. Methods The clinical features, efficacy, and safety in patients with advanced hepatocellular carcinoma who received anti-PD-1 antibody-based therapy were retrospectively analyzed. The survival status was followed-up. Results The objective response and the disease control rate were 21.8% and 76.4%, respectively. The overall incidence of adverse events during treatment was 81.8%, of which the incidence of grade 3/4 adverse events was 14.5%. The incidence of immune-related adverse events was 58.2% and the incidence of grade 3/4 immune-related adverse events was 3.6%, and no treatment-related death was observed. The median PFS of the 55 patients was 5.0 (95%CI: 3.9-6.1) months, and the median OS was 11.4 (95%CI: 6.5-16.3) months. Univariate and multivariate analyses showed that liver function Child-Pugh scores and performance status ECOG score were the influencing factors of the objective response rate and survival. Conclusion In the real world anti-PD-1 antibody-based therapy is safe and effective in patients with advanced hepatocellular carcinoma, in which the performance status ECOG score and liver function Child-Pugh score before treatment are independent prognostic factors influencing survival.
